Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 05, 2020 09:15 ET | Source: Homology Medicines, Inc.

Homology Medicines Announces Upcoming Oral Presentation on pheNIX Gene Therapy Clinical Trial for Adults with PKU

Homology Webcast / Conference Call Scheduled for Friday, November 6 at 4:30 p.m. ET BEDFORD, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines...
October 22, 2020 08:30 ET | Source: Homology Medicines, Inc.

Homology Medicines Unveils New In Vivo Gene Therapy Development Program for Hunter Syndrome

HMI-203 Leverages Ability to Cross Blood-Brain-Barrier Following I.V. Administration, and Preclinical Data Showed Improvements in Key Disease Biomarkers Program Expands Homology’s CNS Portfolio ...
September 18, 2020 09:00 ET | Source: Homology Medicines, Inc.

Homology Medicines to Participate in Upcoming Conferences

BEDFORD, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following virtual...
August 10, 2020 16:05 ET | Source: Homology Medicines, Inc.

Homology Medicines Reports Second Quarter 2020 Financial Results and Provides Business Update

Three Cohorts Enrolled in Phase 1/2 pheNIX Gene Therapy Trial for PKU Progressed Into Later Stages of IND-Enabling Studies for MLD Gene Therapy and PKU Gene Editing Programs and Published Key Data ...
July 21, 2020 08:00 ET | Source: Homology Medicines, Inc.

Homology Medicines Appoints Jeff Poulton to the Board of Directors

- Executive with Extensive Rare Disease Expertise in Global Finance and Commercial Operations - BEDFORD, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic...
May 26, 2020 14:10 ET | Source: Homology Medicines, Inc.

Homology Medicines Announces Peer-Reviewed Publication Describing Molecular Characterization of Precise In Vivo Nuclease-Free Gene Editing with PKU Program

- Methods Showed Efficient On-Target Gene Integration with No Unintended DNA Modifications - BEDFORD, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic...
May 12, 2020 08:00 ET | Source: Homology Medicines, Inc.

Homology Medicines Announces Presentations on its In Vivo Gene Therapy and Gene Editing Programs and Commercial Manufacturing Platform at the American Society of Gene & Cell Therapy Annual Meeting

- Molecular Methods Quantified Precision and Efficiency of Nuclease-Free Gene Editing for PKU - - Manufacturing Enhancements Led to Improved Productivity, Quality and Scalability of Commercial...
May 07, 2020 16:05 ET | Source: Homology Medicines, Inc.

Homology Medicines Reports First Quarter 2020 Financial Results and Recent Highlights

- Progressed the pheNIX Trial for PKU and Added Clinical Sites, Completed Clinical Supply for Phase 1/2 and Began Manufacturing Pivotal Supply - - Executed Commercial Manufacturing Process at...
April 29, 2020 08:00 ET | Source: Homology Medicines, Inc.

Homology Medicines Announces Presentations at Upcoming American Society for Gene & Cell Therapy Annual Meeting

BEDFORD, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today upcoming presentations demonstrating the broad applicability...
March 16, 2020 09:00 ET | Source: Homology Medicines, Inc.

Homology Medicines Announces Peer-Reviewed Publication of HMI-102 Investigational Gene Therapy Demonstrating Restoration of Normal Metabolic Pathway in PKU Disease Model

- Data Package Supported Initiation of Ongoing pheNIX Clinical Trial for Adults with PKU - BEDFORD, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic...